Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of Immunization With the MAGE-3.A1 Peptide Mixed With the Immunological Adjuvant CpG 7909 in Patients With Metastatic Melanoma

NCT00145145 is registered in ClinicalTrials.gov with Ludwig Institute for Cancer Research as lead sponsor.

NCT NCT00145145
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00145145 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of Immunization With the MAGE-3.A1 Peptide Mixed With the Immunological Adjuvant CpG 7909 in Patients With Metastatic Melanoma
Lead sponsor
Ludwig Institute for Cancer Research
Phase
Phase 1/2
Overall status
Terminated
Start date
January 12, 2005
Completion date
April 28, 2008
Enrollment
1 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

malignant melanoma